Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02304367 · ClinicalTrials.gov registry record · Phase 2

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

A Phase 2 study of Tumor-induced Osteomalacia (TIO) and Epidermal Nevus Syndrome (ENS), sponsored by Kyowa Kirin.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
7
Study locations

NCT02304367 is a Phase 2 study of Tumor-induced Osteomalacia (TIO) and Epidermal Nevus Syndrome (ENS) that has completed, run by Kyowa Kirin. The registered enrollment target is 17 participants. The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02304367, a Phase 2 study of Tumor-induced Osteomalacia (TIO) and Epidermal Nevus Syndrome (ENS), has completed, sponsored by Kyowa Kirin.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
7
Study locations

Study Summary

The primary objectives of this study are to evaluate the effect of burosumab treatment on: * Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia * Improvement in TIO/ENS-associated osteomalacia as determined by osteoid thickness (O.Th), osteoid surface/bone surface (OS/BS), osteoid volume/bone volume (OV/BV) and mineralization lag time (MLt).

Interventions

  • BIOLOGICAL Burosumab

Study Locations (7)

Colorado

  • Colorado Center for Bone Research at Panorama Orthopedics and Spine Center - Golden

Connecticut

  • Yale University School of Medicine - New Haven

Indiana

  • Indiana University Hospital - Indianapolis

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • Duke University - Durham

Texas

  • Houston Methodist Research Institute - Houston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-03-24
Est. Completion 2021-01-21
Phase Phase 2

Sponsor

Kyowa Kirin

34 total trials

What the Registry Record Tells You About NCT02304367

The ClinicalTrials.gov registry entry for NCT02304367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tumor-induced Osteomalacia (TIO) appearing as the primary indexed condition, and to 1 intervention - of which Burosumab is the first listed.

NCT02304367 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Connecticut, Indiana.

Frequently Asked Questions

What is clinical trial NCT02304367 about?

NCT02304367 is a clinical study titled "Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)". The primary objectives of this study are to evaluate the effect of burosumab treatment on: * Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia * Improvement in TIO/ENS-associated osteomalacia as determined by osteoid thickness (O.Th), osteoid surface/bone surface ...

What is the current status of trial NCT02304367?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-03-24. Estimated completion is 2021-01-21.

What conditions does trial NCT02304367 study?

This clinical trial studies the following conditions: Tumor-induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS).

What interventions are being tested in trial NCT02304367?

The interventions under investigation include: Burosumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02304367?

This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02304367 being conducted?

This trial has 7 study locations across Colorado, Connecticut, Indiana, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tumor-induced Osteomalacia (TIO)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.